Calliditas is dedicated to expanding treatment options and establishing new standards of care for people with rare diseases. By drawing on our expertise in pharmaceutical product development and leveraging our strategic partnerships, we quickly and efficiently identify, develop, and market a pipeline of innovative medicines that can improve the lives of patients.
Recently, we successfully commercialized our lead candidate in the United States, and in collaboration with our partners, launched in Europe, with plans to seek approval in Asia.
Kungsbron 1, 11122 Stockholm – Sweden
Jan. 1, 2000Stock exchange(s)